Pharmaceutical - AstraZeneca

Filter

Current filters:

AstraZeneca

Popular Filters

1 to 25 of 312 results

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Positive Ph III data for AstraZeneca’s lesinurad in gout patients

17-11-2014

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results of two pivotal Phase III…

allopurinolAnti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Almirall profits leap in first nine months of 2014

Almirall profits leap in first nine months of 2014

10-11-2014

Almirall, Spain’s largest drugmaker, has reported strong financial results for the first-three quarters…

AlmirallAstraZenecaEkliraFinancialPharmaceuticalSpain

AstraZeneca’s olaparib shows success in tumor response rate for patients with BRCA-related cancers

07-11-2014

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26%…

AstraZenecaLynparzaolaparibOncologyPharmaceuticalResearch

AstraZeneca raises forecast on strong third quarter

AstraZeneca raises forecast on strong third quarter

06-11-2014

AstraZeneca, the Anglo-Swedish pharma major which defended itself against a £73.82 billion ($118 billion)…

AstraZenecaFinancialPharmaceutical

UPDATE: AstraZeneca divests Myalept for $325 million

06-11-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a definitive agreement…

Aegerion PharmaceuticalsAstraZenecaMergers & AcquisitionsMyaleptPharmaceuticalRare diseases

Isis Pharmaceuticals receives first $7.5 million milestone payment from AstraZeneca for ISIS-STAT3

Isis Pharmaceuticals receives first $7.5 million milestone payment from AstraZeneca for ISIS-STAT3

05-11-2014

US pharma company Isis Pharmaceuticals has earned the first of two milestone payments from Anglo-Swedish…

AstraZenecaIsis PharmaceuticalsISIS-STAT3RxOncologyPharmaceuticalResearchUSA

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

04-11-2014

MedImmune, a US subsidiary of Anglo-Swedish pharma major AstraZeneca has entered into an agreement to…

AstraZenecaDefiniensMedImmuneMergers & AcquisitionsOncologyPharmaceutical

AstraZeneca and University of Glasgow partner to form immunology discovery center

AstraZeneca and University of Glasgow partner to form immunology discovery center

04-11-2014

The University of Glasgow and Anglo-Swedish drug major AstraZeneca have now officially launched the GLAZgo…

AstraZenecaImmunologicalsPharmaceuticalResearchUK

Almirall transfers rights to respiratory business to AstraZeneca

Almirall transfers rights to respiratory business to AstraZeneca

03-11-2014

Spanish pharma company Almirall has transferred the rights to its respiratory franchise to Anglo-Swedish…

AlmirallAstraZenecaEkliraPharmaceuticalResearchRespiratory and PulmonarySpain

US FDA approves AstraZeneca’s Xigduo XR

US FDA approves AstraZeneca’s Xigduo XR

30-10-2014

The US Food and Drug Administration has approved Anglo-Swedish pharma major AstraZeneca’s once-daily…

AstraZenecaDiabetesPharmaceuticalRegulationUSAXigduo XR

AstraZeneca partners with Manchester University on improving drug delivery and efficacy

AstraZeneca partners with Manchester University on improving drug delivery and efficacy

30-10-2014

Anglo-Swedish drug major AstraZeneca has entered into a strategic collaboration with the University of…

AstraZenecaHealth Medical PharmaPharmaceuticalResearchUK

AstraZeneca’s Lynparza backed for approval by EMA committee

AstraZeneca’s Lynparza backed for approval by EMA committee

24-10-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…

AstraZenecaEuropeLynparzaolaparibOncologyPharmaceuticalRegulation

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

16-10-2014

Anglo-Swedish drug major AstraZeneca, together with its global biologics R&D arm MedImmune, has entered…

AstraZenecaNeurologicalPharmaceuticalResearchUK

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

Brilinta preferred over clopidogrel in latest AHA/ACC guideline

06-10-2014

Anglo-Swedish pharma major AstraZeneca today confirmed that the American Heart Association (AHA) and…

AstraZenecaBrilintaCardio-vascularClopidogrelDaiichi SankyoEli LillyPharmaceuticalprasugrelRegulationSanofiticagrelorUSA

Roche could lose its dominant market share in breast cancer, says IMS report

Roche could lose its dominant market share in breast cancer, says IMS report

03-10-2014

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs,…

AstraZenecaGlobalHerceptinMarkets & MarketingNovartisOncologyPharmaceuticalRochetamoxifen

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

01-10-2014

The annual congress of the European Society for Medical Oncology (ESMO) came to a close in Madrid, Spain,…

AstraZenecaAZD9291IressaOncologyPharmaceuticalResearchUK

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

1 to 25 of 312 results

Back to top